A framework for advancing our understanding of cancer-associated fibroblasts. by Sahai, Erik et al.
UCSF
UC San Francisco Previously Published Works
Title
A framework for advancing our understanding of cancer-associated fibroblasts.
Permalink
https://escholarship.org/uc/item/4490v59t
Journal
Nature reviews. Cancer, 20(3)
ISSN
1474-175X
Authors
Sahai, Erik
Astsaturov, Igor
Cukierman, Edna
et al.
Publication Date
2020-03-01
DOI
10.1038/s41568-019-0238-1
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Cancer arises from mutations accruing within cancer 
cells, but both disease progression and responses to 
therapy are strongly modulated by non- mutant cells 
within the tumour microenvironment. The past few 
years have witnessed a great expansion in research 
into cancer- associated fibroblasts (CAFs). These cells 
modulate cancer metastasis through synthesis and 
remodelling of the extracellular matrix (ECM) and pro-
duction of growth factors, and influence angiogenesis, 
tumour mechanics, drug access and therapy responses. 
More recently, there has been a growing appreciation 
of the ability of CAFs to modulate the immune system. 
Targeting CAFs, by altering their numbers, subtype or 
functionality, is being explored as an avenue to improve 
cancer therapies. However, research in this area faces 
numerous challenges — not least because CAFs can have 
both protumorigenic and antitumorigenic effects. This 
Consensus Statement follows a recent Banbury Center 
meeting at Cold Spring Harbor Laboratory (New York, 
USA) held in March 2019, which focused on CAF bio-
logy and therapeutic opportunities and included an 
open discussion to identify the challenges facing CAF 
research and suggest ways forward (Box 1). On the basis 
of this, we, as an international group of cancer research-
ers and clinician scientists, herein present the current 
state of CAF research, summarize the challenges ahead 
and present both methodological advice and concep-
tual suggestions to provide the necessary framework to 
advance the field.
What is a fibroblast?
The definition of a fibroblast is surprisingly tricky1,2. The 
embryonic origin of most fibroblasts is from the primi-
tive mesenchyme that develops out of the mesoderm fol-
lowing gastrulation3, with a smaller subset of fibroblasts 
also derived from the neural crest, which is part of the 
ectoderm4. This embryonic origin is shared by other 
mesenchymal lineages, including adipocytes, chondro-
cytes and osteoblasts. The difficulty in defining fibroblasts 
results largely from the lack of unique markers that are 
not expressed in any other cell types. The result is that in 
practical terms, fibroblasts are often defined by a com-
bination of their morphology, tissue position and lack of 
lineage markers for epithelial cells, endothelial cells and 
leukocytes. Vimentin and platelet- derived growth factor 
receptor- α (PDGFRα) are sometimes used but typically 
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Abstract | Cancer- associated fibroblasts (CAFs) are a key component of the tumour 
microenvironment with diverse functions, including matrix deposition and remodelling, 
extensive reciprocal signalling interactions with cancer cells and crosstalk with infiltrating 
leukocytes. As such, they are a potential target for optimizing therapeutic strategies against 
cancer. However, many challenges are present in ongoing attempts to modulate CAFs for 
therapeutic benefit. These include limitations in our understanding of the origin of CAFs and 
heterogeneity in CAF function, with it being desirable to retain some antitumorigenic functions. 
On the basis of a meeting of experts in the field of CAF biology, we summarize in this Consensus 
Statement our current knowledge and present a framework for advancing our understanding 
of this critical cell type within the tumour microenvironment.
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Neural crest
Migratory mesenchymal cells 
derived from the neural tube 
and originally the ectoderm.
Adipocytes
Mesenchymal cells specialized 
for the storage of fat.
Pericytes
Mesenchymal cells that are 
located adjacent to smaller 
blood vessels and that support 
their function.
alongside other criteria such as cell shape and location. 
Markers for fibroblast subtypes also exist, including 
α- smooth muscle actin (αSMA; also known as ACTA2) 
and fibroblast activation protein (FAP)5,6, with the sub-
set of fibroblasts expressing the latter playing roles in 
bone and fat homeostasis. Recent work is beginning to 
trace the lineage of fibroblasts from the earliest stage of 
mesenchyme specification through to the adult. This has 
already highlighted distinct subsets of dermal fibroblasts 
and is starting to provide more precise combinations of 
markers with which to define fibroblasts7,8. However, the 
links between lineage commitment in early development 
and the fibroblast subsets found in the adult remain, for 
the most part, to be determined.
In normal development and physiology, fibroblasts 
are the major producers of connective tissue ECM, with 
emerging data indicating that this function is modified 
with age9,10. They also play a key role in tissue repair and 
become activated following tissue damage11. During 
wound healing they can produce transforming growth 
factor- β (TGFβ) and acquire a highly contractile pheno-
type associated with the expression of αSMA12. In this 
state, fibroblasts are termed ‘myofibroblasts’. Both in 
normal homeostasis and following injury they partici-
pate in crosstalk with adjacent epithelia, with numerous 
studies documenting an ability to influence local epi-
thelial stem cell behaviour13,14. They can also promote 
angiogenesis via the production of vascular endothelial 
growth factor A (VEGFA)15 and coordinate the function 
of the immune system via the production of chemokines 
and cytokines, although it should be noted that there 
is heterogeneity in the cytokines produced by different 
fibroblasts16–20. Fibroblasts also play a structural role 
within the immune system; fibroblastic reticular cells 
(FRCs) within lymph nodes generate ECM conduits for 
the transit of potential antigens and serve as migration 
‘highways’ for leukocytes21. This allows effective immune 
surveillance. In addition, they promote immune toler-
ance by the expression and presentation of normally 
tissue- restricted antigens22. Emerging work is revealing 
complex crosstalk between fibroblastic cells and epithe-
lial cells in exocrine organs. For example, stellate cells are 
a distinctive type of fibroblast found in the liver and pan-
creas that store lipid droplets and particular derivatives 
of retinoic acid. The balance between quiescence and 
activation of stellate cells is regulated by the vitamin D 
receptor, deletion of which leads to spontaneous liver 
and pancreas fibrosis23, with further work indicating 
that stellate cells play a broader role in metabolic homeo-
stasis24–26. Thus, fibroblasts are not simply producers of 
ECM but play key roles in communicating with many 
other cell types during both normal tissue homeostasis 
and repair.
What is a CAF?
To first consider how CAFs are generated, it is important 
to try to define CAFs. Many of the same issues arising 
for normal fibroblasts also apply to CAFs. When analys-
ing tissue biopsy samples, the simplest view is that cells 
negative for epithelial, endothelial and leukocyte markers 
with an elongated morphology and lacking the mutations 
found within cancer cells might be considered CAFs. The 
latter point is important because it excludes cancer cells 
that have undergone a profound epithelial to mesenchy-
mal transition (EMT), although such cells are likely to 
be of considerable importance and warrant studying in 
their own right. In practice, lineage exclusion is typically 
combined with positivity for a mesenchymal marker, 
often vimentin; however, this may not be sufficient to 
exclude other mesenchymal lineages such as pericytes 
or adipocytes. Early experimental studies indicated 
that such cells cultured from tumours have distinctive 
properties compared with normal fibroblasts27. In prac-
tice, any mesenchymal cell cultured from a tumour that 
complies with the criteria described above is considered 
a CAF. Nevertheless, as discussed in the section entitled 
‘Challenges and recommendations’, how durable CAF 
subsets and phenotypes remain once fibroblasts are 
isolated and cultured warrants further investigation.
Author addresses
1The Francis crick Institute, london, uK.
2Marvin and concetta Greenberg Pancreatic cancer Institute, Fox chase cancer center, 
Philadelphia, Pa, uSa.
3cancer Biology Program, Marvin & concetta Greenberg Pancreatic cancer Institute,  
Fox chase cancer center, Philadelphia, Pa, uSa.
4Division of oncology, Washington university Medical School, St louis, Mo, uSa.
5cold Spring harbor laboratory, cold Spring harbor, NY, uSa.
6Gene expression laboratory, Salk Institute for Biological Studies, la Jolla, ca, uSa.
7howard hughes Medical Institute, Salk Institute for Biological Studies, la Jolla, ca, uSa.
8Weill cornell Medicine, New York, NY, uSa.
9Institute for Tumor Biology and experimental Therapy, Georg- Speyer-haus,  
Frankfurt, Germany.
10Frankfurt cancer Institute, Goethe university Frankfurt, Frankfurt, Germany.
11Fred hutchinson cancer research center, Seattle, Wa, uSa.
12Molecular and cell Biology laboratory, Salk Institute for Biological Studies, la Jolla,  
ca, uSa.
13Koch Institute for Integrative cancer research, Massachusetts Institute of Technology, 
cambridge, Ma, uSa.
14edwin l Steele laboratories, Department of radiation oncology, Massachusetts 
General hospital, harvard Medical School, Boston, Ma, uSa.
15Northwell health cancer Institute, New hyde Park, NY, uSa.
16cancer research uK Manchester Institute, university of Manchester, Nether alderley, uK.
17Department of radiation oncology, Perlmutter cancer center, New York university 
Medical center, New York, NY, uSa.
18Brown Foundation Institute of Molecular Medicine, The university of Texas health 
Sciences center at houston, houston, TX, uSa.
19Northwell health cancer Institute, New York, NY, uSa.
20Department of Pathology, Stony Brook university, Stony Brook, NY, uSa.
21Department of Biomedical Sciences, School of veterinary Medicine, university  
of Pennsylvania, Philadelphia, Pa, uSa.
22Zucker School of Medicine at hofstra/Northwell health System, New York, NY, uSa.
23Department of Biomolecular Sciences, The Weizmann Institute of Science, rehovot, Israel.
24Department of cell, Developmental & cancer Biology, oregon health & Science 
university, Portland, or, uSa.
25Department of cell Biology and Physiology, Department of Medicine, Icce Institute, 
Siteman cancer center, Washington university School of Medicine, St louis, Mo, uSa.
26ucSF helen Diller comprehensive cancer center, San Francisco, ca, uSa.
27Department of Pathology, ucSF, San Francisco, ca, uSa.
28centre for Stem cells and regenerative Medicine, King’s college london, Guy’s hospital, 
london, uK.
29center for Bioengineering and Tissue regeneration, Department of Surgery, university 
of california, San Francisco, San Francisco, ca, uSa.
30Sidney Kimmel cancer center, Johns hopkins School of Medicine, Baltimore, MD, uSa.
31Department of anatomy, university of california, San Francisco, San Francisco, ca, uSa.
32Present address: abramson cancer center, university of Pennsylvania,  
Philadelphia, Pa, uSa.
  voluMe 20 | March 2020 | 175NaTure revIeWS | CANCer
C o n S e n S u S  S tat e m e n t
Box 1 | Generation of this Consensus Statement
This Banbury center meeting convened experts to discuss 
our current understanding of cancer- associated fibroblast 
(caF) biology, with an emphasis on optimizing new 
approaches being developed to probe the fundamental 
properties of caFs, and medical applications of caF 
targeting. Following the introductory remarks, the idea of 
summarizing the outputs from the meeting in a consensus 
Statement was proposed and unanimously approved. 
An open discussion with all meeting participants was  
held on the final day of the meeting to collate ideas about 
what the consensus Statement should contain and  
how it should be structured. a draft statement was then 
circulated to all authors for feedback and refinement, 
leading to agreement with the views expressed in this 
consensus Statement.
What is the origin of CAFs?
The lack of precision around fibroblast- specific markers 
poses a challenge when one is considering the origin of 
CAFs. When the markers of both normal tissue- resident 
fibroblasts and CAFs are ill- defined, it becomes very 
hard to propose hypotheses regarding the precise cell of 
origin of CAFs. To partially circumvent this problem, 
many studies have documented the changes in the fibro-
blastic component of carcinomas as they progress from 
hyperplasia, through adenoma or in situ lesion, to frank 
carcinoma in patients28. These studies using human 
tissue observe progressive changes in the fibroblastic 
stroma. In many cases, the initial apparent expansion 
of fibroblasts precedes the conversion to malignancy, 
and fibroblasts are often observed circumscribing 
early or premalignant lesions29,30. The gradual nature 
of the transitions observed has given rise to the view 
that the majority of stromal fibroblasts initially origi-
nate from local fibroblasts that experience some form of 
tissue dysfunction31,32. The expansion of stromal fibro-
blast number could result from proliferation, which has 
been experimentally observed in tumours, albeit with 
low frequency33. This process has been termed ‘stroma-
genesis’, with the implication that it proceeds along-
side and is coupled to tumorigenesis34. Furthermore, 
experimental studies and observations of early lesions 
encircled by fibroblasts support the idea that the ini-
tial fibroblast response can be tumour suppressive35,36, 
with subsequent events in stromagenesis generating 
protumorigenic fibroblasts. It is currently difficult to 
explore this hypo thesis in human tissue biopsy sam-
ples because longitudinal sampling of the same lesion 
through disease progression is rarely possible and, even 
when it is, the conversion between cell states cannot be 
directly tracked.
To shed more light on the origin of CAFs, many 
researchers have turned to mouse models in which cells 
can be irreversibly labelled using transgenic techniques 
and well- characterized models of disease progression are 
available. These typically use tissue- restricted expres-
sion of the Cre recombinase in mice that also contain 
a reporter gene that becomes irreversibly active in cells 
that express Cre. Importantly, the active reporter will 
be inherited by all daughter cells and will continue to be 
expressed even if the Cre recombinase is not37. However, 
the lack of fibroblast- restricted markers causes problems 
when one is selecting a promoter to drive the expression 
of the Cre recombinase. This is exemplified by the diver-
gent phenotypes observed in a colitis model of stromal 
knockout of Ikkb (inhibitor of nuclear factor- κB (NF- κB) 
kinase subunit- β) depending on whether a collagen 
type I α2 chain (Col1a2) or collagen type V α1 chain 
(Col5a1) Cre driver was used38,39. The most widely used 
fibroblast drivers and their caveats are detailed in the 
section entitled ‘Challenges and recommendations’. This 
approach can also be used to explore hypotheses includ-
ing the conversion of adipocytes, pericytes, endothelial 
cells and bone marrow- derived mesenchymal stem cells 
(MSCs) into CAFs. The injection of bone marrow- 
derived MSCs into tumour- bearing mice has demon-
strated that they can become CAFs40, with more recent 
studies supporting the MSC origin of PDGFRα– CAFs41. 
Adipocyte conversion into CAFs has been reported by 
several groups, although it does not appear to be a uni-
versally applicable phenomenon across different tumour 
types42–45. The reduction or absence of adipocytes in 
pathological tissue could also result from activated fibro-
blasts interfering with adipocyte differentiation46. In situ-
ations where adipocytes remain, they can engage in 
crosstalk with cancer cells and provide metabolic sup-
port independently of conversion into CAFs47. Evidence 
for pericyte conversion into CAFs is relatively sparse48, 
with tumorigenesis studies that targeted pericytes speci-
fically not revealing large- scale differences in the tumour 
microenvironment.
Ultimately, lineage tracing studies in mice remain 
hampered by the lack of highly specific Cre drivers for 
normal fibroblasts, difficulties of combining lineage 
tracing with genetically engineered models of mouse 
tumours that are also driven by Cre recombinase, the 
suboptimal nature of cell line- based tumour models 
and the lack of incentives to report negative data in such 
studies. Currently, it is also unclear whether individual 
CAF populations are preserved across tissues and spe-
cies. While single- cell sequencing indicates common 
traits are preserved49–51, it will become increasingly 
pressing to define common and specific effects of CAFs. 
Techniques that provide spatial resolution, such as highly 
multiplexed antibody- based staining and multiplexed 
nucleic acid in situ hybridization, will also have a role 
to play in determining whether CAF subtype is strongly 
influenced by spatial location within the tumour. 
Together, these factors mean that definitive conclusions 
on the origin of CAFs are hard to reach. The consensus 
is that most CAFs likely result from the activation of 
local tissue- resident fibroblasts but that there are clear 
examples of alternative origins.
How are CAFs generated?
The studies described in the previous section aimed to 
document which cells give rise to CAFs but do not provide 
a mechanism for their conversion. Given the prominent 
role fibroblasts play in coordinating the wound repair 
response in skin, it is plausible that key CAF traits cor-
respond to the normal physiological role fibroblasts play. 
Well- established activating signals for fibroblasts 
include TGFβ family ligands and the lipid mediator 
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lysophosphatidic acid52–54, which promote the activity 
of the SMAD transcription factors and serum response 
factor (SRF), respectively, and converge to drive expres-
sion of the activated fibroblast marker αSMA as well 
as increase the activity of the contractile cytoskeleton6 
(Fig. 1). Contact between cancer cells and fibroblasts can 
promote the CAF phenotype in breast cancer through 
Notch signalling55; however, this mechanism is unlikely 
to be universal as loss of Notch signalling can promote 
CAF phenotypes in squamous cell carcinoma56. Various 
inflammatory modulators can promote CAF activation, 
with interleukin-1 (IL-1) acting through NF- κB and 
IL-6 acting primarily on signal transducer and activa-
tor of transcription (STAT) transcription factors57,58. 
Crosstalk and positive feedback involving Janus kinase 
(JAK)–STAT signalling, the contractile cytoskeleton 
and alterations in histone acetylation further promote 
CAF activation59,60. Physical changes in the ECM are 
also capable of activating CAFs53,61–64. In vitro stud-
ies have shown that fibroblast stretching, which may 
result from the hyperproliferation of transformed epi-
thelial cells, can activate SRF- driven transcription and 
Yes- associated protein 1 (YAP1)–TEAD- driven trans-
cription53,54,65,66. These transcription factors cooperate to 
drive the expression of a wide- range of genes associated 
with CAFs, including the genes encoding connective 
tissue growth factor (CTGF; also known as CCN2) and 
cysteine- rich angiogenic inducer 61 (CYR61; also known as 
CCN1)54. Furthermore, matricellular molecules, such 
as CTGF and CYR61, and the contractile cytoskeleton 
cooperate to increase tissue stiffness, which further 
drives SRF- dependent and YAP1-dependent transcrip-
tional programmes, locking CAFs into a self- sustaining 
positive- feedback loop53. Physiological stress is also 
another factor contributing to stromagenesis. Heat 
shock factor 1 (HSF1), which responds in part to protein 
misfolding, is required for the generation of CAFs67,68. 
Physiological and genomic stresses can also trigger 
changes in fibroblasts. Double- stranded DNA breaks can 
promote the production of IL-6 and the TGFβ family 
ligand activin A69,70. In some cases, these triggers cause 
fibroblasts to enter a non- proliferative state termed 
‘senescence’71, which is distinct from the phenotype of 
an aged fibroblast. There is clear overlap between the 
secretome of senescent fibroblasts and CAFs, with high 
levels of IL-6 production being common to both, and 
senescent fibroblasts have been found in the micro-
environment of some tumours72. The non- proliferative 
nature of senescent cells makes it unlikely that they are 
a major contributor to the abundant stromal fibroblasts 
observed in desmoplastic tumours73. Nonetheless, it 
remains possible that CAFs and senescent fibroblasts 
share some transcriptional regulatory mechanisms74,75. 
Furthermore, even if senescent fibroblasts are a minor 
component of the tumour microenvironment, experi-
mental analysis suggests that their elimination can have 
substantial consequences for disease relapse71.
In addition to considering tumour cells as the direct 
source of cues that generate CAFs, signals from other 
cells within the tumour microenvironment may also 
instruct CAF function; for example, granulin produced 
by macrophages promotes the activation of a fibrotic 
environment in liver metastases76,77. Such mechanisms 
that do not directly depend on the presence of cancer 
may contribute to the protumorigenic environments 
found in inflammatory conditions that are linked to 
increased cancer risk. In addition, cancer therapies, 
including conventional chemotherapies, radiotherapy 
and targeted agents, can promote the generation of 
CAFs and modulate their functionality. These changes 
can aid the development of therapy resistance78–80 and 
contribute to undesirable side effects80. Being able to 
mitigate these events is another potential appeal of 
CAF- directed therapies.
The expanding range of CAF functions
The functions of CAFs have been determined using 
a variety of strategies, ranging from reductionist cell 
culture experiments and mouse models to correlative 
associations in large patient cohorts. These approaches 
have revealed a diverse array of functions (Fig. 2). The 
relative ease of culturing CAFs and matched normal 
fibroblasts from patient material has greatly facili-
tated mechanistic delineation of CAF functions. CAFs 
are perhaps the most effective cell within the tumour 
microenvironment at depositing and remodelling 
the ECM. This depends on RHO and RAB GTPase- 
mediated control of integrin- mediated adhesions and 
the actomyosin cytoskeleton81–83 and is linked to down-
regulation of the transmembrane receptor CD36 (also 
known as platelet glycoprotein 4)84. CAFs also produce 
matrix- crosslinking enzymes and, together with force- 
mediated ECM remodelling (reviewed in detail85,86), 
these contribute to the increased stiffness of tumour 
tissue87–89. Although chemical crosslinks are not readily 
reversed, the production of matrix proteases allows the 
tumour matrix to be remodelled, and this can lead to 
the generation of permissive tracks that allow cancer 
cell invasion81. Contact- mediated Eph–ephrin signalling 
further influences cancer cell migration90. In addition to 
promoting local invasion, CAFs are able to boost meta-
stasis in experimental models, and this correlated with 
their ability to remodel the ECM91–93. Once cancer cells 
Inflammatory signals
(IL-1, IL-6 and TNF)
Extracellular matrix
(stiffness and composition)
TGFβ
RTK ligands (PDGF and FGF)Contact signals(Notch and Eph–ephrins)
Physiological stress
(ROS and disrupted
metabolism)
DNA damage
(chemotherapy
and radiotherapy)
CAF 
activation
Normal fibroblast
CAF
Fig. 1 | Diverse mechanisms of cancer- associated fibroblast activation. This schematic 
highlights the multiple mechanisms that can contribute to cancer- associated fibroblast 
(CAF) activation. FGF, fibroblast growth factor; PDGF, platelet- derived growth factor; 
ROS, reactive oxygen species; RTK, receptor tyrosine kinase; TGFβ, transforming growth 
factor- β; TNF, tumour necrosis factor.
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have disseminated, the de novo activation of fibroblasts 
at secondary sites favours the establishment of macro-
metastases via multiple mechanisms, including the 
production of matrix components such as tenascin and 
periostin that provide supporting signals to the cancer 
cells94,95. These molecules boost WNT signalling94, which 
may link to the role of some fibroblasts in normal physio-
logy in regulating stem cell niches that are rich in WNT 
ligands96,97. More recently, changes in ECM organization 
have been shown to influence the migration of infiltrat-
ing leukocytes, which has implications for the immune 
surveillance of tumours98.
The alterations in matrix production and tumour 
mechanics that result in a large part from the action of 
CAFs have complex consequences for tumours. Increased 
tissue stiffness triggers prosurvival and proproliferation 
signalling in cancer cells99. Increased mechanical stress 
can collapse blood vessels, leading to hypoxia, thereby 
promoting more aggressive cancer phenotypes, and 
reducing drug delivery89,100–105. Altered tissue mechan-
ics are also likely to play a role in cancer development 
and premalignant disease; this is evidenced by the links 
between mammographic density and breast cancer inci-
dence84. Targeting the interplay between CAFs and the 
mechanical properties of tumours for patient benefit is 
currently being explored (see TABlE 1).
CAFs are also a substantial source of growth factors, 
cytokines and exosomes that can promote tumour 
growth and modulate therapy responses27,106–108. The 
production of TGFβ, leukaemia inhibitory factor (LIF), 
growth arrest- specific protein 6 (GAS6), fibroblast 
growth factor 5 (FGF5), growth differentiation factor 15 
(GDF15) and hepatocyte growth factor (HGF) pro-
motes invasive and proliferative behaviour in cancer 
cells52,109–112. In addition, HGF has been implicated in 
mediating resistance to BRAF- targeted therapies by pro-
viding an alternative BRAF- independent mechanism for 
ERK–MAPK activation113.
The secretome of CAFs also influences other com-
ponents of the tumour microenvironment. VEGF 
expression by stromal cells can drive angiogenesis15,114. 
Numerous cytokines and chemokines are produced by 
CAFs, and these act on a range of leukocytes, including 
CD8+ T cells, regulatory T (Treg) cells and macrophages, 
with both immunosuppressive and immunopromot-
ing consequences115. However, the consensus is that 
the predominant effect of CAFs is immunosuppres-
sive with IL-6, CXC- chemokine ligand 9 (CXCL9) and 
TGFβ having well- established roles in reducing T cell 
responses116. More recently, antigen cross presentation 
by CAFs has been observed117, and this may lead to CD4+ 
T cell activation and suppression of CD8+ T cells118. 
Clinical analysis further supports an inverse associa-
tion between CAFs and CD8+ T cells119. IL-6 may also 
promote immunosuppression via systemic effects on 
metabolism120. Interference with the action of CXCL12 
produced by CAFs promotes T cell- mediated tumour 
control16,121,122, and targeting focal adhesion kinase (FAK) 
in cancer cells concomitantly reduces stromal fibro-
blast activation and the development of an immuno-
suppressive environment123. However, the situation with 
tumour necrosis factor (TNF) produced by CAFs is more 
nuanced; the tumour- promoting immunosuppressive 
activity of FAP+ fibroblasts is associated with suppression 
of TNF signalling, yet TNF is also able to drive fibroblast 
activation in certain contexts16,124,125.
The exchange of metabolites and amino acids 
between cancer cells and CAFs is an additional ave-
nue by which stromal fibroblasts interact with tumour 
cells126–129. Autophagy in stromal fibroblasts can generate 
Immune crosstalk
• TGFβ activation
• IL-6 production
• CXCL12 
production
• CCL2 production
Soluble secreted 
factors
• VEGF
• Exosomes
• HGF and GAS6 
production
Matrix remodelling
• Matrix crosslinking
• Proteolysis
• Force-mediated 
matrix remodelling
• Matrix production
Metabolic effects
• Lactate shuttling
• Alanine and aspartate shuttling
• Amino acid depletion
Macrophage 
and endothelial 
crosstalk
CAF Interference with
T cell function
Cancer invasion
Tumour growth
Fig. 2 | Summary of cancer- associated fibroblast functions and the mechanisms by which they are achieved.  
Dark blue text boxes indicate the biological functions being regulated, with light blue, green, purple and grey text boxes 
indicating the processes and mechanisms leading to the control of function. Lines connect mechanisms to functions.  
Both matrix remodelling and the production of soluble factors contribute to increased tumour cell invasion. Soluble 
factors also contribute to changes in tumour growth and the immune microenvironment, which is also affected by the 
altered metabolic state of the tumour. CAF, cancer- associated fibroblast; CCL2, CC- chemokine ligand 2; CXCL12,  
CXC- chemokine ligand 12; IL-6, interleukin-6; GAS6, growth arrest- specific protein 6; HGF, hepatocyte growth factor; 
TGFβ, transforming growth factor- β; VEGF, vascular endothelial growth factor.
Focal adhesion kinase
(FAK). A kinase that links 
integrin extracellular matrix 
receptors to intracellular 
changes in cell signalling.
Tumour necrosis factor
(TNF). A cytokine that is 
produced under conditions  
of tissue stress and promotes 
inflammation.
Autophagy
A process of cellular ‘self- 
eating’ that serves to remove 
damaged organelles and 
provide metabolic resources.
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alanine, which is subsequently used by pancreatic ductal 
adenocarcinoma (PDAC) cells to fuel the tricarbo x-
ylic acid (TCA) cycle126,130,131. Furthermore, metabolic 
dysregulation of CAFs may also be coupled to altered 
immunoregulation, possibly through IL-6 production 
or depletion of immunomodulating amino acids128,132.
CAF heterogeneity and plasticity
The large array of functions attributed to CAFs in a 
range of model systems poses the question of whether 
a single type of CAF simultaneously performs all these 
functions or whether there is subspecialization of CAFs 
and possibly switching between distinct functional 
states. Overwhelming evidence now points to a degree 
of specialization among CAFs, which may reflect the 
increasingly appreciated specialization of normal 
fibroblasts19,50. This is informed by the increasing array 
of functional assays combined with the emergence of 
single- cell technologies, including single- cell RNA 
sequencing48,49,133. New analyses are being reported at 
an impressive rate, and the field is in a state of flux. 
Nonetheless, there is a recurrent observation of distinct 
CAFs exhibiting either a matrix- producing contractile 
phenotype or an immunomodulating secretome — 
often termed ‘myoCAFs’ and ‘iCAFs’, with the prefixes 
alluding to a myofibroblast phenotype and regulation of 
inflammation, respectively. In pancreatic cancer, CAFs 
most proximal to the cancer cells exhibit a myoCAF 
phenotype, with high TGFβ- driven αSMA expression 
and a contractile phenotype33. More distal CAFs exp-
ress higher levels of IL-6 and are labelled iCAFs. The 
apparent exclusivity of the two phenotypes can be 
explained by TGFβ- mediated suppression of the IL-1 
receptor, which is responsible for driving NF- κB sig-
nalling and subsequent IL-6 expression20. Breast 
cancer also shows divergent CAF phenotypes, with 
the primary discriminating marker being FAP. FAP- 
high fibroblasts are correlated with Treg cell- mediated 
immuno suppression and a poor outcome119, which is 
broadly consistent with the tumour rejection observed 
following the ablation of FAP+ fibroblasts in experi-
mental systems16. However, FAP+ fibroblasts should 
Table 1 | Current cancer- associated fibroblast clinical trial activity
Target Name Drug or biologic Mechanism Current status
Interference with CAF activation
FGFR JNJ-42756493 Small- molecule inhibitor Prevents CAF activation Phase I and phase II trials 
under way170
Hedgehog IPI-926 (saridegib)  
and vismodegib
Small- molecule inhibitor Reduces CAF activation Clinical trials ongoing; some 
reported lack of efficacy169,171
Interference with CAF activation and CAF action
TGFβ Various, including 
galunisertib
Both blocking Abs and 
small- molecule receptor 
inhibitors
Prevents CAF activation and 
immunosuppression
Phase I, phase II and phase III 
trials under way172,173
Angiotensin receptor Losartan Small- molecule inhibitor Reduces collagen and hyaluronan 
levels
Phase II trial completed; 
randomized trial ongoing174,175
Interference with CAF action
CXCR4 AMD3100 Small- molecule inhibitor Prevents signalling from CAFs  
to immune cells
Clinical trials ongoing176
ROCK AT13148 Small- molecule inhibitor Reduces contractility Phase I trial completed177
FAK Defactinib (VS-6063, 
PF-04554878)
Small- molecule inhibitor Reduces signalling downstream  
of integrins
Clinical trials ongoing178
LOXL2 Simtuzumab (GS 6624) Blocking Ab Anticrosslinking Preclinical and fibrosis trials179
CTGF FG-3019 Blocking Ab Blocks binding to receptors, 
including integrins
Early- phase clinical trials 
ongoing
Hyaluronic acid PEGPH20 (PVHA) Pegylated enzyme ECM degradation to increase the 
access and efficacy of cytotoxic 
therapies and immunotherapies
Phase III trial complete, 
awaiting final analysis180,181
FAP- expressing cells Various, including 
PT630 and RO6874281
Blocking Abs (sibrotuzumab I 
(rEF.182), molecular 
radiotherapy, inhibitors 
(PT630) or an Ab–IL-2 fusion 
(RO6874281)
Blocks FAP+ CAF function, 
promoting T cell function
Phase I and phase II trials 
under way183
CAF normalization
Vitamin A metabolism ATRA Vitamin A metabolite ‘Normalizes’ stellate cells Clinical trials ongoing184,185
Vitamin D receptor Paricalcitol Small- molecule agonist ‘Normalizes’ stellate cells Clinical trial started186
Ab, antibody; ATRA, all- trans retinoic acid; CAF, cancer- associated fibroblast; CTGF, connective tissue growth factor; CXCR4, CXC- chemokine receptor 4;  
ECM, extracellular matrix; FAK, focal adhesion kinase; FAP, fibroblast activation protein; FGFR, fibroblast growth factor receptor; IL-2, interleukin-2;  
LOXL2, lysyl oxidase- like 2; ROCK, RHO kinase; TGFβ, transforming growth factor- β.
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not be viewed as solely immune modulating, as their 
targeting with chimeric antigen receptor (CAR) T cells 
leads to reduced matrix deposition134. Another study 
reported an NF- κB-driven subset of CAFs express-
ing GPR77 and CD10, which promote ‘stemness’ and 
chemoresistance within breast cancer cells135. In the 
long term, it will be important for researchers to coa-
lesce around a consensus for CAF subtypes and nomen-
clature (discussed in more detail later). Improvements 
in multi plexed immunohistochemistry that allow the 
analysis of multiple markers simultaneously and more 
quantitative methods for determining relative degrees of 
marker expression should aid reproducible evaluation 
of CAF subtypes.
The issue of CAF heterogeneity raises additional 
questions; including whether CAF subtypes might 
interconvert or whether they are more stable, possibly 
because they are instructed by oncogenic or tumour 
suppressor mutations within cancer cells. Knowledge 
in this area is currently emerging. Work in PDAC has 
shown how KRAS mutation or different p53 mutational 
status can influence CAFs111,136. Mutant p53 drives 
TNF production by cancer cells, leading to enhanced 
matrix remodelling and perlecan expression by CAFs136. 
However, such studies do not preclude additional non- 
genetic factors influencing CAF subtype. Indeed, CAFs 
isolated from mouse PDAC can be switched from the 
αSMA- high and IL-6-producing states through manipu-
lation of TGFβ and IL-1 signalling, arguing for con-
siderable plasticity in fibroblast states20. Furthermore, 
the responsiveness of matrix production by fibroblasts 
and the αSMA promoter to a range of extracellular 
cues, including substrate stiffness, supports the idea 
that the αSMA- high, matrix producing- high state 
is rever sible63,64,137–139. Once again, irreversible line-
age marking approaches in mouse models should be 
informative in addressing the interconvertibility of 
different CAF subtypes, and improved understanding 
of the epigenetic regulation of CAF states should shed 
further light on the stability of CAFs.
Targeting CAFs for clinical benefit
Many patient studies have documented how either CAF 
number or CAF function is linked to outcome140–142, 
and thus being able to target CAFs would represent 
an appealing addition to the suite of anticancer thera-
pies. Further targeting mechanisms, such as TGFβ sig-
nalling, that activate CAFs or emanate from CAFs to 
modulate the tumour phenotype are being intensively 
explored143,144. There is already much activity in the area 
of CAF targeting — summarized in Box 2, TABlE 1 and 
detailed reviews145,146. However, the breadth of CAF 
functions and possible interconvertibility of subtypes 
poses a challenge for the field, with preclinical studies 
suggesting that the non- specific targeting or deletion of 
stromal fibroblasts may not enhance tumour control35,36. 
Thus, patient benefit might require targeting of CAF 
subtypes or reprogramming of CAFs to either a normal 
fibroblast or an antitumorigenic CAF phenotype. This 
highlights the importance of defining CAF subtypes and 
their inter- relationships. One appealing strategy is to 
make CAFs more ‘normal’. An example of this approach 
is provided by the targeting of the vitamin D receptor in 
pancreatic cancer. Treatment with a vitamin D receptor 
ligand caused activated stellate cells to revert to a more 
quiescent state and reduced disease aggressiveness23,147 
(see TABlE 1). Therefore, it is important to delineate 
whether individual fibroblast populations represent 
‘states’ and are therefore interconvertible or whether dis-
tinct ‘lineage- restricted’ effects exist as this may dictate a 
different therapeutic approach. The functional contribu-
tion of CAFs to tumour biology is also typically assumed 
to be preserved across tumour types, but this remains to 
be demonstrated, and care will be needed when one is 
extrapolating between different tumour types.
In practice, achieving clinical benefit may not neces-
sarily require elimination or reprogramming of CAFs, 
but could be achieved by blocking signals coming from 
the CAFs. For example, targeting CXCL12 signalling 
could be considered to be targeting CAFs as they are 
the major source of the chemokine in many tumours121. 
Similarly, targeting ECM components and down-
stream signalling represents a means of interfering with 
CAF–cancer cell communication. Indeed, many existing 
therapies influence CAF–cancer cell communication and 
already modulate how CAFs affect cancer cells. As men-
tioned earlier, BRAF inhibitors can activate stromal 
fibroblasts and thereby promote a compensatory mech-
anism for activating ERK–MAPK in cancer cells78. Many 
of the expanding range of receptor tyrosine kinase inhib-
itors have some activity on FGF and PDGF receptors 
that can drive fibroblast function148,149. This is exempli-
fied by the repurposing of nintedanib, which was origi-
nally developed with oncology in mind, for treatment 
of idiopathic pulmonary fibrosis150. Finally, both conven-
tional DNA damaging chemotherapy and radiotherapy 
Idiopathic pulmonary 
fibrosis
A life- limiting progressive 
condition involving persistent 
activation of fibroblasts and 
inflammation in the lungs.
Box 2 | Cancer- associated fibroblast clinical trial activity
cancer- associated fibroblasts (caFs) are increasingly viewed as a target that could  
be manipulated for therapeutic benefit in patients with cancer. There are now many 
clinical trials involving caF- targeting agents in combination with existing therapies. 
The underlying rationale is that by targeting caFs there will be improvements in the 
access of either conventional therapies or T cells to the tumour. In some cases, new 
strategies are being developed to target fibroblasts specifically (for example, fibroblast 
activation protein (FaP) ligands coupled to cytotoxic drugs165). In other cases, crosstalk 
between cancer cells and fibroblasts is targeted (for example, hedgehog pathway 
inhibition166), or existing compounds are found to have a strong influence on caF 
functions and are repurposed as anti- stromal drugs (for example, losartan is primarily 
used to treat high blood pressure but also modulates the tumour extracellular 
matrix100,101,167,168). TABlE 1 outlines ongoing clinical trial activity in these areas.
Possible lessons from targeting the Hedgehog pathway in pancreatic cancer
The clinical trial designed to recapitulate the advantageous effect of hedgehog 
pathway inhibition in mouse models of pancreatic ductal adenocarcinoma (PDac)166 
failed to show such benefit and paradoxically reported decreased patient survival in 
combination with gemcitabine chemotherapy (NcT01130142)169. The details of this trial 
have not yet been described, and subsequent preclinical studies that suppressed in the 
long term the caF subset known to be hedgehog responsive also demonstrated more 
rapid PDac progression35,36. one possible explanation for this discordance between the 
first mouse experiments and the latter ones, and the failed clinical trial, is that caFs are 
interconvertible from hedgehog responsive to hedgehog non- responsive over time, 
and this should be considered in the design of new studies. Indeed, it is now common 
practice for clinical trials to evaluate the numbers of different classes of T cells, and it 
would be an important advance if data on caF numbers and subtypes, at least based 
on some key markers, were also captured.
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can trigger changes in CAF biology, with fibrosis being 
a common late side effect of radio therapy151. These data 
argue that more studies to assess the extent to which 
responses to therapies might be influenced by altered 
CAF biology are warranted.
Challenges and recommendations
An emerging framework for nomenclature. A key chal-
lenge now facing researchers of CAF biology is nomen-
clature (Box 3). Ideally a system should be simple enough 
to allow it to be used by the wider cancer and stromal 
biology communities but not so dogmatic and con-
strictive that it masks subtle variations in function 
and markers. In addition, it must have flexibility to 
incorporate fibroblast subtypes that are only currently 
being revealed by single- cell transcriptomics and mass 
cytometry methods. Although our view was that it is 
too soon for definitive nomenclature to be established, 
the consensus was that the main determinant of CAF 
cate gorization should be function, informed primarily 
by direct experimental evidence and, in some cases, 
robust clinical correlation analyses. These categories 
should then be linked to markers, ideally cell surface 
markers, so that they can be further interrogated in 
analyses that might not be compatible with functional 
testing. A sensi ble starting point for such a classification 
would be the reiteration that activated fibroblasts can 
adopt a high matrix producing and remodelling state 
— analogous to the myofibroblast in other pathologies. 
This is linked to high levels of TGFβ signalling and 
αSMA expression6. It will also be necessary to include 
immunomodulation into CAF categories. Although 
most studies have suggested an immuno suppressive role 
of CAFs121, it should be left open that CAFs could pro-
mote immune- mediated tumour surveillance. Indeed, 
the function of FRCs in lymph nodes is to make possible 
an effective T cell- mediated immune response21. Scope 
should also be left for antigen presentation, the meta-
bolic state of fibroblasts, and their lineage history to be 
incorporated into any nomenclature.
Robust and standardized methods for detecting CAFs 
in tissue. Progress in translational studies will require 
accurate recording of CAF numbers and subtype within 
clinical samples. Clinical studies that target either CAFs 
or CAF- associated functions must include measurement 
of CAFs in their design. More generally, our consensus 
was that CAF metrics should be recorded even in stud-
ies that do not have CAFs as their focus, for example 
in immuno- oncology trials. This will depend on high- 
quality antibodies against CAF marker proteins, which 
in many cases are lacking. While reliable αSMA anti-
bodies are available, antibodies against putative CAF 
subtype markers often require painstaking optimization, 
and this hampers their adoption in clinical pathology 
laboratories. The technology around multiplexed mRNA 
probes is developing rapidly and, in the long term, this 
might provide a better and more flexible solution than 
antibody- based methods. Furthermore, researchers are 
aware of caveats in studies that involve dissociation of 
tumour tissue, for example those using cytometry by 
time of flight (CyTOF) and single- cell RNA sequencing. 
Detaching fibroblasts from tissue typically requires more 
aggressive methods than for leukocytes, and there is risk 
that fibroblasts are substantially under- represented in 
studies optimized for leukocyte biology152.
Measuring CAF functions in vitro and in vivo. The diver-
sity of CAF function is reflected in the wide range of 
assays used to assess CAF function. While the breadth 
of assays is necessary, it presents a challenge when one is 
interpreting the literature. In this subsection, we review 
the main assays used and highlight key points regarding 
interpretation of their results.
The function of CAFs can be directly investigated 
in vitro. Given the ability of both serum and stiff sub-
strates to activate fibroblasts, attention should be paid to 
the culture conditions used, with lower serum concentra-
tions and matrices with more physiological mechanical 
properties being preferable. Furthermore, it is impor-
tant to consider whether the CAFs being tested are early 
passage primary cells or have been in culture for several 
passages and even immortalized. Although certain CAF 
characteristics are stably maintained in culture, such as 
their increased ability to remodel the ECM53, it is highly 
likely that some traits are not. Detailed characterization 
of how CAF properties change on isolation and longer- 
term culture will help to clarify which functional assays 
necessitate early passage primary CAFs and which work 
equally well after longer periods of cell culture.
Matrix production and remodelling can be easily 
measured. CAFs will produce ECM in culture, and this 
can be assayed for its composition and quantity using 
western blotting, quantitative immuno fluorescence and 
mass spectrometry methods153. The organization of this 
matrix can be determined by immuno fluorescence, 
frequently staining for fibronectin, and its mechani-
cal properties can be determined by either atomic force 
microscopy or shear rheology. Similar techniques can be 
applied in vivo, with collagen second- harmonic imaging  
frequently used to assess matrix organization. Multi-
parametric magnetic resonance imaging (MRI) and 
magnetic resonance elastography (MRE) can also be 
Box 3 | Key recommendations
• adoption of a simple, non- constrictive nomenclature 
based on cancer- associated fibroblast (caF) function
• relate fibroblast markers to function while avoiding 
dogmatic schemes that do not account for diversity  
of fibroblast states
• Determine the lineage relationship of different  
caF subtypes
• Prioritize identification of strategies that can 
reprogramme caFs rather than ablate them
• Increased reporting of caF metadata in experimental 
studies, including clinical features of the tumour, caF 
marker expression in the original tumour, short tandem 
repeat profile, culture conditions and passage number, 
and immortalization
• recording of caF numbers in clinical studies and  
trials, starting with reporting of α- smooth muscle  
actin (αSMa) and fibroblast activation protein (FaP) 
staining
Atomic force microscopy
A method for determining the 
mechanical properties of cells 
and tissue with high precision.
Shear rheology
The characterization of flow or 
deformation originating from  
a simple shear stress field.
Second- harmonic imaging
A label- free method for 
detection of collagen fibres  
in both live and fixed tissue.
Magnetic resonance 
elastography
(MrE). A method for 
interrogating tissue mechanics 
in patients.
  voluMe 20 | March 2020 | 181NaTure revIeWS | CANCer
C o n S e n S u S  S tat e m e n t
used to infer tissue mechanics, with the advantage that 
these techniques can be translated to clinical imaging 
and used in clinical trials154,155. Histochemical stains to 
distinguish collagen, including Masson’s trichrome and 
picrosirius red, provide similar information and the use 
of crossed polarizing filters during imaging of picro sirius 
red- stained sections provides a measure of collagen 
crosslinking156. However, most methods for the analy-
sis of pattern lack universal quantitative metrics; in the 
future, the implementation of methods from network 
topology analysis and the use of spatial statistics will aid 
comparison between studies157,158.
The secretome of CAFs is typically measured using 
enzyme- linked immunosorbent assay (ELISA) and cyto-
kine array tools, with a range of standardized commercial 
reagents available. Exosomes can be analysed following 
their purification by high- speed centrifugation with 
clear guidelines on optimal protocols159. Crosstalk 
with cancer cells is usually evaluated in terms of changes 
in growth and invasion. Cells can be directly co- cultured, 
with either genetic labels or staining for markers used 
to distinguish the cancer cells and fibroblasts, indirectly 
co- cultured (that is, separated by a filter) or conditioned 
media can be exchanged between separate cultures. 
Cell number is the most common growth metric, and 
migration either into a 2D ‘wound’ or across a Trans-
well are most common invasion metrics. Advances in 
3D co- cultures, including the use of organoid cultures 
and reconstituted matrices, are allowing in vitro assays 
to more closely mimic the in vivo tissue architecture. 
In these assays, it should be noted that basement mem-
brane preparations often contain growth factors in 
addition to matrix components, leading to the possible 
confounding of matrix and growth factor influences on 
CAF biology. Pepsinized preparations of collagen I lack-
ing the telopeptide cannot be crosslinked, which leads 
to altered dependencies on matrix metalloproteinases 
(MMPs) for cancer invasion160. Co- cultures with other 
cell types from the tumour microenvironment can 
also be informative. For example, fibroblasts can boost 
angiogenesis in in vitro assays, with exciting advances in 
the development of microfluidic angiogenesis models, 
and an increasing number of studies have shown how 
they can alter T cell functionality118,161,162.
Two main methods are used to explore CAF func-
tions in vivo: transgenic manipulations and co- injection 
methods. The latter are simpler to perform as they 
avoid the need for complex mouse crosses. However, 
there are some notable caveats. The most challenging 
is that as tumours grow they will contain a mixture of 
the co- injected CAFs and fibroblasts derived from the 
host mouse and, for reasons that are not fully under-
stood, host- derived fibroblasts outgrow co- injected 
CAFs. In practice, this favours the early evaluation of 
differences between experimental groups and makes 
it hard to test longer term phenotypes, such as therapy 
responses. Transgenic manipulations using Cre–lox sys-
tems to modulate CAFs overcome these issues but have 
a different set of issues. The most notable of these is the 
choice of the Cre driver line. Currently, no CAF- specific 
Cre driver line exists, and even fibroblast- specific Cre 
driver lines are complex. Acta2-Cre and Acta2-Cre–ERT 
can be used, but they will also drive recombination in 
smooth muscle cells and myoepithelial cells, which 
poses a particular challenge in mouse models of breast 
cancer, which has a high frequency of these cell types in 
the tumour microenvironment. Fsp1-Cre has the caveat 
that fibroblast- specific protein 1 (FSP1; also known 
as S100A4) is expressed by subsets of myeloid cells. 
Pdgfra- Cre and Col1a2-Cre are more generic fibroblast 
drivers, but the former gene is expressed in some neu-
rons and the latter is expressed in osteoblasts. These 
issues highlight the importance of using ‘Cre- reporter 
mice’ to check that recombination is being driven in 
the intended subset of cells and not more permissively. 
Following its expression, Cre recombinase can then be 
used to specifically knock out suitably ‘floxed’ genes in 
fibroblasts or inhibit or ablate fibroblasts by driving the 
expression of viral thymidine kinase or diphtheria toxin 
receptor, respectively.
The other major challenge with in vivo models is how 
to drive tumorigenesis if the Cre–lox system is used to 
manipulate CAFs. Injection of tumour cells can be used, 
but this is not always ideal as it bypasses the early stages 
of tumour initiation. Chemical carcinogenesis is another 
option, but it is not always easy to control tumour bur-
den, and the cancer genotypes will be variable. Finally, 
combining Cre–lox and Flp–FRT (flippase recognition 
target) recombination systems offers an elegant way to 
manipulate both tumour and fibroblasts163. Once the 
tumour is established, various metrics relating to CAF 
function can be measured, including matrix organization 
and crosslinking, tissue mechanics, tumour vascular-
ization, tumour growth, metastatic spread, immune 
infiltrate and therapy response. However, this approach 
is very resource and time intensive, and this poses a 
barrier for many researchers.
An awareness of the caveats of the assays described 
above and subsequent improvements to the methods will 
aid further progress. The use of CAFs that have been 
established in culture allows molecular perturbations, 
such as CRISPR gene editing, and the easy repetition 
of experiments. In the future it will be desirable to 
determine primary culture conditions that most accu-
rately preserve the in vivo phenotype of CAFs; this is 
likely to involve considering both the medium and the 
substrate, with several studies showing how culture in 
3D conditions can return fibroblasts to their original 
pheno type within tissue10,142. Combining this with ongo-
ing improvements in the ability to manipulate primary 
cells will allow assays with human cells that more closely 
mimic the tumour context. For analysis of interplay with 
T cells, it will be desirable to isolate cancer cells, CAFs 
and tumour- infiltrating lymphocytes from the same 
patient. Improvements in tumour tissue slice culture 
methods should also be considered for the analysis of 
CAF biology.
Reporting CAF metadata. As with all experimental sci-
ence, the issue of reproducibility is crucial. Research 
into CAFs is greatly made possible by their ability to be 
cultured in vitro, but the process of cell culture and the 
exact conditions can influence cell behaviours. Increased 
reporting of CAF metadata will improve standardization 
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Short tandem repeat 
profiles
Variation in repetitive sequences 
between individuals used  
to unambiguously identify  
cell lines.
and robustness in the field. We recommend that studies 
involving CAFs document the following:
• An absence of the mutations that drive the tumour 
from which they originate. CAFs may accrue muta-
tions, but it is necessary to exclude that they are simply 
cancer cells that have undergone EMT. Cancer cells 
that have undergone a profound EMT clearly warrant 
detailed study and comparison with CAFs, but these 
cells should be considered distinct from CAFs.
• The spatial position within the tumour from which 
the biopsy was taken — central versus margin. If 
‘normal’ fibroblasts are isolated at the same time from 
non- cancerous tissue, then the distance of this tissue 
from the margin should be recorded.
• Key clinical (stage, grade, prior treatment regimen 
and driver mutations (if known)) and histological 
features of the tumour from which the CAFs origi-
nate, including ideally staining for CAF markers and 
the age of the patient or mouse.
• Short tandem repeat profiles of cultured CAFs to 
allow unambiguous identification of CAFs in subse-
quent studies. This will mitigate against inadvertent 
cross- contamination of cultures.
• The passage number of cultured CAFs and the 
immortalization method used, if any. Details of 
the culture medium should also be recorded; in parti-
cular, serum percentage, addition of exogenous TGFβ, 
culture substrate or matrix (including type of Matrigel 
and whether collagen I is telopeptide intact).
Conclusions
Research into CAFs is at an exciting and critical stage. 
Accumulating functional analyses in preclinical models 
and supporting correlative analyses of patient material 
indicate that improved treatment strategies should be 
possible by targeting CAFs. Indeed, several clinical trials 
are under way. However, targeting aspects of the tumour 
microenvironment has a chequered history, with 
failures in the area of MMP inhibition, mixed results in 
targeting angiogenesis and transformative results 
with inhibition of T cell immune checkpoints in some 
cancers164. Therefore, translating the optimism in the 
CAF field into real clinical benefits will require careful 
attention to trial design and tumour sample analysis. 
Attention needs to be paid to nomenclature and the cor-
rect description of different CAF subtypes. This is more 
than just a semantic issue as the greatest success is likely 
to come from either targeting specific CAF subsets or 
interconverting CAF subtypes. Related to this, a better 
understanding is needed of the relationship between 
CAFs observed in preclinical models, which often grow 
very rapidly in young adult mice, as opposed to those in 
patients, which progress more slowly in an older popu-
lation. Improved assay standardization and reporting 
of CAF metadata will assist this endeavour. There are 
also opportunities to incorporate analysis and report-
ing of CAF numbers and types in clinical studies that 
are not primarily focused on fibroblast biology, such as 
immuno- oncology and targeted therapy trials. This will 
help to build a more complete picture of the relationship 
between CAFs and therapy responses and highlight new 
areas in which combining a CAF- targeted agent with 
existing therapies could yield greater bene fit. With these 
things in place, we are confident that CAF- targeted 
therapy will take its place in the toolkit of the oncologist 
within the next 10 years.
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